TauRx Alzheimer's Drug LMTX Fails in Large Study Although Some Benefit Seen

 

By Reuters

CHICAGO — TauRx Pharmaceuticals' experimental Alzheimer's drug LMTX failed to improve cognitive and functional skills in patients with mild to moderate Alzheimer's disease, a large, late-stage study showed.

But in a perplexing twist, the drug did show a significant benefit in about 15 percent of patients in the trial who were not taking other standard Alzheimer's drugs, according to the findings released on Wednesday at the Alzheimer's Association International Conference in Toronto. 

Claude Wischik, co-founder of Singapore-based TauRx and a professor of geriatric psychiatry at Aberdeen University, said in that so-called "monotherapy" group, the drug reduced the rate of decline in cognitive and functional skills by 85 percent.

Dr. Laurie Ryan, chief of the Dementia of Aging Branch at the National Institute on Aging, called the finding "intriguing," but said "it doesn't tell us a lot yet at this point." 

Click here for the full article.

Source: NBC News